Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Study in Subjects Using Levemir (Insulin Detemir), NovoMix 30 (Biphasic Insulin Aspart 30) [insulin aspart/insulin protamine aspart] and/or NovoRapid (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus.

Trial Profile

Efficacy and Safety Study in Subjects Using Levemir (Insulin Detemir), NovoMix 30 (Biphasic Insulin Aspart 30) [insulin aspart/insulin protamine aspart] and/or NovoRapid (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Insulin aspart; Insulin aspart/insulin protamine aspart; Insulin detemir
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Jul 2012 Additional locations added as reported by ClinicalTrials.gov.
    • 23 Oct 2009 Actual initiation date changed from Mar 2008 to Feb 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top